Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease

Hepatology Research

Volumn 44, Issue 7, 2014, Pages 812-817

  Oza, Noriko ^a   Takahashi, Hirokazu ^a   Eguchi, Yuichiro ^a   Kitajima, Yoichiro ^b   Kuwashiro, Takuya ^a   Ishibashi, Eriko ^a,b   Nakashita, Shunya ^a   Iwane, Shinji ^a   Kawaguchi, Yasunori ^a   Mizuta, Toshihiko ^a   Ozaki, Iwata ^a   Ono, Naofumi ^b   Eguchi, Takahisa ^b   Fujimoto, Kazuma ^a   Anzai, Keizo ^a  

^a SAGA UNIVERSITY   (Japan)

^b Eguchi Hospital   (Japan)

Author keywords

Diet; Dyslipidemia; Exercise; Ezetimibe; Low density lipoprotein cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LIFESTYLE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RASH; TREATMENT DURATION;

EID: 84903850162     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12176     Document Type: Article

References (36)

1. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gatroenterology 2002; 123: 134-140.
2. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gatroenterology 2005; 129: 375-378.
3. Söderberg C, Stål P, Askling J etal. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
4. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
5. Speliotes EK, Massaro JM, Hoffmann U etal. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-1987.
6. Taskinen MR, Adiels M, Westerbacka J etal. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 2011; 31: 2144-2150.
7. Oza N, Eguchi Y, Mizuta T etal. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009; 44: 1203-1208.
8. Ekstedt M, Franzén LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
9. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009; 44: 1236-1243.
10. Rafiq N, Bai C, Fang Y etal. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
11. Garcia-Calvo M, Lisnock J, Bull HG etal. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005; 102: 8132-8137.
12. Kalogirou M, Tsimihodimos V, Gazi I etal. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23: 1169-1176.
13. Yoneda M, Fujita K, Nozaki Y etal. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010; 40: 613-621.
14. Park H, Shima T, Yamaguchi K etal. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107.
15. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134-1139.
16. Shiwa T, Kawanami Y, Yokoyama T, Moritani A, Hashimoto M, Gotoh T. The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD). Nihon Shokakibyo Gakkai Zasshi 2011; 108: 1383-1392.
17. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
18. Fujimoto K, Sakata T, Etou H etal. Charting of daily weight pattern reinforces maintenance of weight reduction in moderately obese patients. Am J Med Sci 1992; 303: 145-150.
19. Ainsworth BE, Haskell WL, Whitt MC etal. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 2000; 32: S498-504.
20. Nakagaichi M, Tanaka K. Development of a 12-min tredmill walk test at a self-selected pace for the evaluation of cardiorespiratory fitness in adult men. Appl Hum Sci 1998; 17: 281-288.
21. Astrand PO, Rodahl K. Applied sports physiology. Astrand PO, Rodahl K, Dahl HA, eds. Textbook of Work Physiology. Psychological Bases of Exercise, 3rd edn. New York: McGraw-Hill, 1986; 646-682.
22. Ministry of Health, Labour and Welfare of Japan. Exercise and physical activity reference for health promotion 2006. Available at: http://www.nih.go.jp/eiken/programs/pdf/epar2006.pdf.
23. Teramoto T, Sasaki J, Ueshima H etal. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
24. Tobin KA, Steineger HH, Alberti S etal. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol Endocrinol 2000; 14: 741-752.
25. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 2004; 101: 11245-11250.
26. James AP, Watts GF, Barrett PH etal. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism 2003; 52: 136-141.
27. Poppitt SD, Keogh GF, Prentice AM etal. Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am J Clin Nutr 2002; 75: 11-20.
28. Anderson JW, Garrity TF, Wood CL, Whitis SE, Smith BM, Oeltgen PR. Prospective, randomized, controlled comparison of the effects of low-fat and low-fat plus high-fiber diets on serum lipid concentrations. Am J Clin Nutr 1992; 56: 887-894.
29. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996; 37: 439-447.
30. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
31. Hyogo H, Tazuma S, Arihiro K etal. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-1718.
32. Abel T, Fehér J, Dinya E, Eldin MG, Kovács A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6-11.
33. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-234.
34. Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol Belg 2007; 70: 381-388.
35. Fernández-Miranda C, Pérez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-205.
36. Hatzitolios A, Savopoulos C, Lazaraki G etal. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-134.